ChelseaDianeGawryletzDO

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Physician

Overview of Dr. Gawryletz

Dr. Chelsea Gawryletz is an oncologist in Fort Collins, CO and is affiliated with multiple hospitals in the area, including UCHealth Poudre Valley Hospital, Intermountain Health Saint Joseph Hospital, and Intermountain Health Good Samaritan Hospital. She received her medical degree from Arizona College of Osteopathic Medicine of Midwestern University and has been in practice 6 years. She is one of 27 doctors at Intermountain Health Saint Joseph Hospital and one of 24 doctors at Intermountain Health Good Samaritan Hospital who specialize in Oncology. She has 3 publications and 28 citings.

Office
2121 E Harmony Rd
Unit 170
Fort Collins, CO 80528
Book by Phone+1(970) 578-3702

Fax+1 970-493-3528

Education & Training

Mayo Clinic College of Medicine and Science (Phoenix)Fellowship, Hematology and Medical Oncology, 2014 - 2017
University of Arizona College of Medicine-PhoenixResidency, Internal Medicine, 2011 - 2014
Arizona College of Osteopathic Medicine of Midwestern UniversityClass of 2011
University of Alaska FairbanksBS, Biochemistry and Molecular Biology, 2002 - 2006

Certifications & Licensure

NE State License 2022 - 2026
CO State License 2018 - 2025
WY State License 2022 - 2025
AZ State License 2011 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Start of enrollment: 2015 Oct 20
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles Start of enrollment: 2017 Apr 28
Recruiting
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors Start of enrollment: 2016 Nov 01
Recruiting
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Start of enrollment: 2019 Apr 05
Active, not recruiting
Phase 3
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer Start of enrollment: 2019 Oct 02
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

6 citations
Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholang...
Jan B. Egan, David L. Marks, Tara L. Hogenson, Anne M. Vrabel, Ashley N. Sigafoos
JCO Precision Oncology. 2017-08-01
5 citations
Crucial considerations for pipelines to validate circulating biomarkers for breast cancer.
Radwa Ewaisha, Chelsea D. Gawryletz, Karen S. Anderson
Expert Review of Proteomics. 2016-01-04
23 citations
Successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis
Juan F. Gallegos-Orozco, CD Paskvan-Gawryletz, Gurudu, R Orenstein
Revista De Gastroenterologia De Mexico. 2012-01-01

Authored Content

Ischemic Neuroprotection of Neuregulin-1 Response Cascade Involves the Ets Repressor FactorJune 2006

Press Mentions

COVID-19 Vaccine Shows New Side Effect as It May Result in False Positive on MammogramsMarch 6th, 2021

Committees

Co-chair, Hematology/Oncology curriculum committee 2018 - 2020

Research History

Translational GenomicsBreast and Ovarian Cancer Research Unit (BOCRU) TGen, Helios Scholar 20082008 - 2018
Biochemistry / molecular biology ResearchSpecialized Neuroscience Research Program (SNRP) graduate researcher, University of Alaska Fairbanks Chemistry Department2005 - 2007
Research fellowMorehouse School of Medicine, National Institute of Health / National Institute of Neurological Disorders and Stroke.2005 - 2005